Octreotide
1
Reactions 1360 - 16 Jul 2011 Octreotide Allergic reaction and hypertension in children: 2 case reports Two children with chronic intestinal pseudo-obstruction developed an allergic reaction and hypertension, respectively, while receiving IV octreotide daily [ages, sexes, dosages and times to reaction onset not stated]. Octreotide was discontinued in the first patient and the second patient responded following dose reduction. These patients were among nine patients identified in a retrospective review. For the group as a whole, the octreotide dosages ranged from 0.2 to 1 µg/kg/day (divided into 1–3 doses) and duration of therapy was 2–15 months. Rodriguez L, et al. Daily intravenous octreotide promotes enteral feeding tolerance in children with chronic intestinal pseudo-obstruction. Journal of Pediatric Gastroenterology and Nutrition 49 (Suppl. 1): E50 abstr. 112, 2009 - USA 801160702 1 Reactions 16 Jul 2011 No. 1360 0114-9954/10/1360-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Octreotide
Reactions 1360 - 16 Jul 2011
Octreotide
Allergic reaction and hypertension in children:2 case reports
Two children with chronic intestinal pseudo-obstructiondeveloped an allergic reaction and hypertension,respectively, while receiving IV octreotide daily [ages,sexes, dosages and times to reaction onset not stated].Octreotide was discontinued in the first patient and thesecond patient responded following dose reduction. Thesepatients were among nine patients identified in aretrospective review. For the group as a whole, theoctreotide dosages ranged from 0.2 to 1 µg/kg/day (dividedinto 1–3 doses) and duration of therapy was 2–15 months.Rodriguez L, et al. Daily intravenous octreotide promotes enteral feeding tolerancein children with chronic intestinal pseudo-obstruction. Journal of PediatricGastroenterology and Nutrition 49 (Suppl. 1): E50 abstr. 112, 2009 -USA 801160702
1
Reactions 16 Jul 2011 No. 13600114-9954/10/1360-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
